Inaxaplin

Inaxaplin targets APOL1 and shows efficacy in proteinuric kidney disease among people with two APOL1 variants. Inaxaplin demonstrates efficacy for proteinuric kidney disease in individuals with two APOL1 variants. Inaxaplin is a drug that targets APOL1 and demonstrates efficacy in treating proteinuric kidney disease in individuals carrying two APOL1 risk variants. Inaxaplin shows efficacy for proteinuric kidney disease in people with two APOL1 variants. Inaxaplin targets APOL1 and demonstrates efficacy in treating proteinuric kidney disease in individuals with two APOL1 risk variants. Inaxaplin is a drug that targets APOL1 and demonstrates efficacy in treating proteinuric kidney disease in individuals with two APOL1 risk variants. Inaxaplin is a drug targeting APOL1 that demonstrates efficacy in treating proteinuric kidney disease. Inaxaplin is a drug that directly targets APOL1 and demonstrates efficacy in treating proteinuric kidney disease. Inaxaplin demonstrates efficacy for proteinuric kidney disease in people with two APOL1 variants. Inaxaplin is a drug that targets APOL1 and demonstrates efficacy in treating proteinuric kidney disease in individuals with two APOL1 variants.…